EDIT
Price
$2.62
Change
+$0.10 (+3.97%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
385.49M
38 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$6.86
Change
-$0.12 (-1.72%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
780.6M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs SLDB

EDIT vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. SLDB commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and SLDB is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
EDIT vs SLDB: Fundamental Ratings
EDIT
SLDB
OUTLOOK RATING
1..100
6086
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
7964
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (25) in the Biotechnology industry is in the same range as EDIT (34). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (99). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's Price Growth Rating (64) in the Biotechnology industry is in the same range as EDIT (79). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that SLDB’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITSLDB
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (EDIT: $2.52 vs. SLDB: $6.98)
Brand notoriety: EDIT and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 50% vs. SLDB: 143%
Market capitalization -- EDIT: $385.49M vs. SLDB: $780.6M
EDIT [@Biotechnology] is valued at $385.49M. SLDB’s [@Biotechnology] market capitalization is $780.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 6 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SLDB is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -8.36% price change this week, while SLDB (@Biotechnology) price change was -6.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 09, 2026.

SLDB is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AVT102.242.29
+2.29%
Avnet
LOB36.390.20
+0.55%
Live Oak Bancshares
XSLLU10.17N/A
N/A
Xsolla SPAC 1
HGBL1.26-0.04
-3.08%
Heritage Global
FIP2.60-0.16
-5.80%
FTAI Infrastructure

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-3.46%
EDIT - SLDB
56%
Loosely correlated
-1.95%
RCKT - SLDB
53%
Loosely correlated
-1.52%
FDMT - SLDB
53%
Loosely correlated
-3.28%
CRBU - SLDB
52%
Loosely correlated
-3.94%
BEAM - SLDB
51%
Loosely correlated
-0.25%
More